Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens.

MLA

the EuroSIDA Study Group, et al. “Incidence of Cancer and Overall Risk of Mortality in Individuals Treated with Raltegravir‐based and Non‐raltegravir‐based Combination Antiretroviral Therapy Regimens.” HIV Medicine, vol. 19, no. 2, Feb. 2018, pp. 102–17. EBSCOhost, https://doi.org/10.1111/hiv.12557.

APA

the EuroSIDA Study Group, Cozzi, L. A., Mocroft, A., Yust, I., Schmid, P., Gottfredsson, M., Khromova, I., Jilich, D., Flisiak, R., Smidt, J., Rozentale, B., Radoi, R., Zangerle, R., Losso, M. H., Machala, L., Zilmer, K., Ristola, M., Pradier, C., Kirk, O., & Lundgren, J. D. (2018). Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens. HIV Medicine, 19(2), 102–117. https://doi.org/10.1111/hiv.12557

Chicago

the EuroSIDA Study Group, Lepri, A. Cozzi, A. Mocroft, I. Yust, P. Schmid, M. Gottfredsson, I. Khromova, et al. 2018. “Incidence of Cancer and Overall Risk of Mortality in Individuals Treated with Raltegravir‐based and Non‐raltegravir‐based Combination Antiretroviral Therapy Regimens.” HIV Medicine 19 (2): 102–17. doi:10.1111/hiv.12557.